Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 50
- Registration Number
- NCT04440267
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Wei Zhao
- Target Recruit Count
- 82
- Registration Number
- NCT04228393
- Locations
- 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Bone ScanDrug: CyclophosphamideProcedure: Computed TomographyDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: CytarabineDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumBiological: Inotuzumab OzogamicinDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseProcedure: Magnetic Resonance ImagingDrug: PrednisoloneOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission TomographyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 500
- Registration Number
- NCT03920813
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiDrug: CyclophosphamideBiological: BlinatumomabDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: Mercaptopurine Oral SuspensionDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: PrednisoloneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Interventions
- Drug: BortezomibDrug: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: MyocetDrug: DoxorubicinDrug: 6-MercaptopurineDrug: EtoposideDrug: Fludarabine PhosphateDrug: PrednisoloneDrug: IfosfamideDrug: TioguaninDrug: PegaspargaseDrug: MethotrexateDrug: ErwinaseDrug: VincristineDrug: Vindesine
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: RuxolitinibDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: VincristineDrug: PegaspargaseDrug: RituximabDrug: Methotrexate (Intrathecal Administration)Drug: Methotrexate (Intravenous Administration)Drug: DexamethasoneDrug: DoxorubicinDrug: ThioguanineDrug: Methotrexate Oral Product
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Interventions
- Drug: ChidamideDrug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-MercaptopurineDrug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.